Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). It still has a long way to go to reach that ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). IgAN is a key focus for Novartis ...

Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development ...

HC Wainwright reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nineteen analysts that are covering the firm, Ratings reports. Eight research ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Piper Sandler adjusted its stance on Q32 Bio Inc. (NASDAQ: QTTB), downgrading the biotech firm's stock rating from Overweight to Neutral and significantly reducing the price target to $4.00 from the ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first recipient of a gene-edited pig kidney died from cardiac causes within 2 ...